- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 209/12 - Radicaux substitués par des atomes d'oxygène
Détention brevets de la classe C07D 209/12
Brevets de cette classe: 611
Historique des publications depuis 10 ans
|
52
|
45
|
48
|
63
|
28
|
37
|
27
|
50
|
31
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 164 |
14 |
| Bristol-myers Squibb Company | 4892 |
12 |
| Janssen Pharmaceuticals, Inc. | 428 |
12 |
| Vertex Pharmaceuticals Incorporated | 1596 |
12 |
| FUJIFILM Corporation | 29228 |
11 |
| Sensorium Therapeutics, Inc. | 31 |
11 |
| BioCryst Pharmaceuticals, Inc. | 177 |
10 |
| The Johns Hopkins University | 5642 |
9 |
| Katholieke Universiteit Leuven | 1174 |
9 |
| California Institute of Technology | 3967 |
8 |
| Novartis AG | 10904 |
7 |
| Kanna Health Ltd. | 12 |
7 |
| Versicolor Technologies, LLC | 10 |
6 |
| The Regents of the University of California | 19812 |
5 |
| Wyeth LLC | 652 |
5 |
| The Board of Trustees of the University of Illinois | 2683 |
5 |
| Medivir AB | 138 |
5 |
| Toyama Chemical Co., Ltd. | 103 |
5 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2837 |
5 |
| F. Hoffmann-La Roche AG | 7926 |
4 |
| Autres propriétaires | 449 |